Afecta Pharmaceuticals Enters Into Research Collaboration Agreement With UCI

Afecta Pharmaceuticals has entered into a research collaboration agreement with the University of California, Irvine (UCI) to interrogate promising drug molecules for the treatment of advanced melanoma using the PharmetRx® AI-based drug discovery and development platform. Dr. Feng Liu-Smith, an Assistant Professor in the Department of Epidemiology at UCI, and Dr. John Schomberg, the Director of Bioinformatics at Afecta Pharmaceuticals, will be spearheading this collaborative effort.